Yale University holds annual bone marrow honor registration drive
The anniversary is especially meaningful, as 17 was Mandi Schwartz's jersey number.
Branford boy with leukemia finds bone marrow match with help from Dan and Andrea Hurley
'To find out that she needed a matching donor, to have the transplant that could save her life, that just inspired everybody on the campus to try to go out, add to the registry, and hopefully find a matching donor for her,' Yale's assistant director of strategic communications, Sam Rubin, said.
Despite their best efforts to find her a match, the 23-year-old lost her battle with acute myeloid leukemia in 2011. However, her legacy lives on through the marrow drives, which have now spread to over 300 schools across the country as part of the NMDP 'Get in the Game'' campaign.
'We heard about Mandi's story and about how hard it is to find a match and we all kind of step up and play our part and try to help everyone who needs it,' Yale hockey player Owen Forester said.
Since Yale started doing the drives in 2009, they've added about 10,000 potential donors and over 100 matches for patients.
Connecticut Families: Brookfield dad gets bone marrow transplant from professional lacrosse player
The registration process takes just a few minutes and involves a cheek swab. Anyone between 18 and 40 can sign up. NMDP said for matches, the procedure is not painful or overly invasive.
'Ninety percent of the donations at this point are what's called a peripheral blood stem cell donation,' which is very similar to a plasma donation that many people are familiar with, according to member recruitment coordinator Jessica Pacheco.
'The 10 percent is that bone marrow donation, which is needed for our pediatric patients, aggressive cancers. But even that's outpatient now, it's not nearly as invasive as it used to be,' Pacheco said.
Yale officials said their goal this year is to get over 600 people to sign up.
'We're going to shoot through that, get as many people as we can and save some lives,' Yale men's soccer player Conrad Lee said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Yale study finds suicide-prevention app effective for psychiatric inpatients
A new study conducted by researchers at Yale School of Medicine and The Ohio State University Wexner Medical Center and College of Medicine has determined that a mobile phone app providing suicide-specific therapy decreased suicidal thoughts among high-risk psychiatric patients. According to the research, the mobile therapy app OTX-202 cut the rate of post-discharge suicide attempts by 58.3% among patients with a history of such behavior. Researchers described this as a significant breakthrough for a population prone to repeated suicidal tendencies. Beyond preventing attempts, the app also helped sustain reductions in suicidal thoughts for up to 24 weeks after psychiatric hospitalization. By comparison, patients using a control app alongside standard treatment initially improved, but their suicidal thoughts returned by week 24. In the wake of the study's findings, the team behind it claims OTX-202 could be a valuable tool for maintaining mental health gains during the vulnerable period following discharge. Targeted therapy crucial as suicide rates increase In the US, suicide ranks among the leading causes of death, with its impact felt across multiple age groups. It is the second leading cause of death for those aged 10–14 and 25–34, the third for individuals aged 15–24, and the fourth for people aged 35–44. Over the past two decades, the national suicide rate has climbed by more than 33%, underscoring the urgent need for effective prevention strategies, the study outlines. More than one million adults in the US engage in nonfatal suicidal behavior each year, with nearly 500,000 hospitalized. Suicide and attempts at taking one's own life cost an estimated $500 billion annually, yet it remains the only leading cause of death without approved prescription treatments for most at-risk patients. According to the study's co-first author Craig Bryan, professor at Ohio State University's Department of Psychiatry and Behavioral Health and director of its suicide prevention program, suicide-specific therapy can be highly effective at reducing suicidal thoughts and urges, but access to trained therapists after hospital discharge is often limited. The mobile app OTX-202 may help close this gap by delivering targeted therapy directly to patients, supporting their recovery and reducing the risk of relapse during the critical post-discharge period. Multi-site randomized trial revealed promising results As part of a multi-site, double-blind randomized controlled trial, researchers from Yale and Ohio State evaluated OTX-202 among 339 psychiatric inpatients across six US hospitals. Participants were assigned either to the OTX-202 app or to an active control app, while being administered standard care. While the control app offered safety planning and psychoeducation, OTX-202 delivered a targeted suicide-specific therapy module. Results showed that patients using OTX-202 were significantly more likely to improve, as measured by the Clinical Global Impression for Severity of Suicide-Change (CGI-SSC) scale—a standardized clinician-rated tool for tracking symptom severity and progress across diverse settings. "Patients and those who care for them do not have access to reliable and effective tools and resources to reduce future suicide risk. This population faces arguably the biggest gap in access to effective interventions of any leading killer. The potential clinical and population health impact of this new option is extraordinary," stated senior author Seth Feuerstein, MD, assistant clinical professor of psychiatry at Yale, in a media release issued by the university.
NBC Sports
13-08-2025
- NBC Sports
Brian Schottenheimer reveals thyroid cancer scare when he was 28
Jerry Jones revealed in the new Netflix documentary, America's Team: The Gambler and His Cowboys, that he overcame stage 4 melanoma more than a decade ago. Cowboys coach Brian Schottenheimer said Wednesday that he is 'glad' Jerry shared his diagnosis and treatment to give people 'hope.' 'It gives people the strength to say 'Hey, you can beat this,'' Schottenheimer said, via video from the team. Schottenheimer, 51, then for the first time shared his own cancer diagnosis at age 28. He showed the scar where doctors removed 17 lymph nodes to rid him of thyroid cancer. 'I knew I had lump in my throat. I knew there was something bothering me, but I didn't think it was anything,' said Schottenheimer, who now is cancer-free. Schottenheimer had just finished a training camp practice more than two decades ago when he received a message to call his doctor. He knew it was bad news and, after hearing it from the doctor, went to tell his father, Marty, who immediately called former Washington owner Dan Synder. Snyder previously had beaten thyroid cancer. 'I broke down. [Marty Schottneheimer] said, 'We'll figure this out and get the best help we can get,'' Schottenheimer said. 'He picked up the phone and called Dan Snyder, a guy that two years before had fired him. . . . I'll never forget: He told me when Dan picked up the phone, and my dad said to him, 'Hey, Dan, I have a problem; Brian has cancer.' Dan said, 'Marty, give me 5 minutes, and I'll call you back,' and I think it was within 24 to 36 hours that I was on the operating table [at the Mayo Clinic] in Rochester, Minnesota. Again, it just shows you when you're dealing with things like that, everything competitively stops.' Schottenheimer said it was 'traumatic' to hear the c-word and to contemplate the unknown. 'Mine was nothing as serious as [Jones' cancer diagnosis],' Schottenheimer said. 'Thyroid cancer is the slowest growing cancer in the world. I was actually more concerned about when I had to have the surgery that I could lose my ability to speak, and I was a coach. They're [operating] around your vocal cords. [Former Bengals and Bucs] Sam Wyche actually had something like that happen to him. . . . It kind of reminds you of what truly matters.' Schottenheimer said that without his position in the NFL and for Synder, his story could have turned out differently.
Medscape
12-08-2025
- Medscape
Does This Side Effect Spell Doom for the GLP-1's?
This transcript has been edited for clarity. Welcome to Impact Factor , your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson from the Yale School of Medicine. About a year ago, I was talking to one of my friends about the slew of studies showing very broad benefits of the GLP-1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Mounjaro). including weight loss and improved diabetes control. But studies also showed improved heart and kidney health, as well as lower overall mortality. Some analyses found reductions in problem drinking, smoking, and even compulsive shopping among people taking these drugs. I told my friend that I thought these drugs were complete game changers, fundamentally 'anticonsumption' agents that are the cure for society's primary ill of overconsumption. 'Yeah, but what about the side effects?' he said. I said, 'Sure, some gastrointestinal issues can come up, but usually it's not that bad.' Still, I demurred, 'It's early days; perhaps after 10 years on the drugs your eyes fall out or something.' This week's study doesn't suggest that GLP-1's cause your eyes to fall out exactly, but, as you'll see in a second, it's not that far off. We're talking about this study, ' Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes,' appearing in JAMA Network Open , which looks at eye problems in people taking the two most potent GLP-1 drugs. This was a huge retrospective cohort study using the TrinetX database, which contains electronic health record data on millions of patients across the United States. Researchers identified more than a million individuals with diabetes in the database who had no history of eye disease. They then identified when they were first prescribed Ozempic, Mounjaro, or a bunch of non-GLP-1 diabetes medications (such as insulin and metformin) which serve as controls here. They were on the lookout for conditions that some smaller studies had suggested might be associated with the weight-loss drugs: disorders of the optic nerve — in particular, a rather rare condition that can occur even outside diabetes, known as non-arteritic anterior ischemic optic neuropathy (NAION). This is a syndrome caused by a decline in blood supply to the optic nerve and is characterized by the sudden and painless loss of eyesight in one eye, which can lead to permanent blindness. It seems straightforward to ask which group — those who got the GLP-1 drugs or those who took other diabetes drugs — had more eye problems. But you probably suspect that these two groups weren't exactly comparable even before they started the drug. People who took weight-loss drugs were younger, more likely to be female, more likely to be on antihypertensive drugs, more likely to have a history of sleep apnea, and much more likely to have obesity. This is a classic apples-vs-oranges problem in observational research, one that was overcome, in this case, through a form of statistical wizardry called propensity score matching. In this process, each patient is assigned a likelihood of being prescribed the weight-loss drug, and then they are matched with someone with similar propensities. Thus, only one of each pair actually received the drug. Naturally, not everyone was matched; the apples and oranges that were just too appley or orangey were dropped from further analysis. After matching, the two groups were much more similar. Now that we have two similar groups — one of orangish apples and the other of appley oranges — we can compare the rates of NAION between them. Of 79,699 individuals started on either Ozempic or Mounjaro, 35 developed NAION within 2 years of follow-up. Of 79,699 started on non-GLP-1 diabetes drugs, 19 developed NAION over a similar duration of follow-up. That's 0.04% compared with 0.02%. There are a couple of ways to look at the data. On the relative scale, we see nearly a doubling of the risk for this eyesight-threatening disorder among people taking GLP-1 drugs. But on the absolute scale, any given individual's chance of actually getting this disorder is vanishingly small; the rate in the GLP-1 group was 462 per million individuals, compared with a baseline rate of about 238 per million individuals. Identifying rare risks like this is still important, especially for drugs that are as widely prescribed as the GLP-1's. Patients and providers need to have this in the back of their minds so that, if an unusual eye symptom does develop, everyone can react quickly. It's still not clear how these drugs could lead to NAION. It's true that the optic nerve has GLP-1 receptors on it, so this could be a direct drug effect. But the researchers suggest other possibilities as well, including the idea that sudden metabolic changes associated with weight loss or glucose effects from the drugs may change the microenvironment of the eye. I hate to fall back on 'more research is necessary,' but the truth is, more research is necessary to figure out how this works and, importantly, who is most at risk. I should remind you that this study shows us correlation, not causation. Even with propensity score matching, there will still be differences between the comparison groups that aren't fully accounted for. Beyond that, the very fact that people may be on alert for eye disorders among those taking GLP-1's may become something of a self-fulfilling prophecy in a study like this. If physicians are primed to think of a rare diagnosis like NAION when they see a patient on a GLP-1 drug, they might be more likely to make the diagnosis than they would if presented with exactly the same symptoms in someone not taking the drug. When the outcome is rare like this, minor biases can drive the results. So, I'm not ready to go back on my statement that these drugs are game changers. They clearly are. But we'd be naive to assume that there wouldn't be some risk. I'm encouraged that this particular risk is not nearly of a magnitude and frequency to counteract the obvious benefits of the drugs. In the end, this is one of those knowledge-is-power things. I don't think we'll see enthusiasm dampen for the GLP-1 drugs because of NAION, but it doesn't hurt for any of us — patients or providers — to be aware of it.
